InnoCare gets approval of clinical trial of Zurletrectinib for the treatment of pediatric patients in China
Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes
Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes
Through the use of robotic assisted orthopaedic surgeries, the success rate is close to 98%
If approved, KEYTRUDA would be the first immunotherapy for the first-line treatment of HER2-positive advanced gastric or GEJ cancer in tumors expressing PD-L1 (CPS ?1) in the EU
Luforbec® 100/6 pMDI aims to provide comprehensive support to patients and healthcare professionals
Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics
The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023
Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026
CMOs showed an increasing reluctance to take on debt in 2022
Subscribe To Our Newsletter & Stay Updated